store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
A 839977是一种选择性 P2X7 受体拮抗剂,具有抗炎和镇痛活性, 可抑制 P2X7 受体的 BzATP 诱发的钙内流,可用于研究肾纤维化 .
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 278 | 现货 | ||
5 mg | ¥ 648 | 现货 | ||
10 mg | 特惠询价 | 现货 | ||
50 mg | 特惠询价 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,130 | 现货 |
产品描述 | A 839977 is a selective P2X7 receptor antagonist with anti-inflammatory and analgesic activity that inhibits BzATP-induced calcium efflux from the P2X7 receptor for the study of renal fibrosis. |
靶点活性 | P2X7 receptor:150 nM (Mouse), P2X7 receptor:42 nM (Rat), P2X7 receptor:20 nM (Human) |
体外活性 |
A 839977 selectively blocks BzATP-evoked calcium influx at mammalian P2X7 receptors (IC50=20-150 nM). A 839977 inhibits agonist-evoked YO-PRO uptake and IL-1beta release from differentiated human THP-1 cells. Furthermore, A 839977 has demonstrated efficacy in reducing inflammatory and neuropathic pain in animal models[1]. In optic nerve astrocytes, pre-treatment with A 839977 (50 nM for 1 hour) significantly prevents the pressure-induced rise of IL-1β priming[3]. |
体内活性 | In rats, A 839977 (30 μmol/kg, 100 μmol/kg, 300 μmol/kg; pre-injected 30 mins) dose-dependently reduces thermal hyperalgesia induced by intraplantar administration of complete Freund's adjuvant (CFA)[1].In the CFA model of inflammatory pain in wild-type mice, A 839977 (10 μmol/kg, 30 μmol/kg, 100 μmol/kg; pre-injected 30 mins) elicits robust antihyperalgesia, while it shows no effect in IL-1alphabeta knockout mice[1].Furthermore, A 839977 attenuates dorsal horn neuronal responses in cancer-bearing animals[2]. |
别名 | A839977, A-839977 |
分子量 | 413.26 |
分子式 | C19H14Cl2N6O |
CAS No. | 870061-27-1 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (193.58 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4198 mL | 12.0989 mL | 24.1978 mL | 60.4946 mL |
5 mM | 0.484 mL | 2.4198 mL | 4.8396 mL | 12.0989 mL | |
10 mM | 0.242 mL | 1.2099 mL | 2.4198 mL | 6.0495 mL | |
20 mM | 0.121 mL | 0.6049 mL | 1.2099 mL | 3.0247 mL | |
50 mM | 0.0484 mL | 0.242 mL | 0.484 mL | 1.2099 mL | |
100 mM | 0.0242 mL | 0.121 mL | 0.242 mL | 0.6049 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
A 839977 870061-27-1 Membrane transporter/Ion channel Metabolism Neuroscience P2X Receptor Calcium Channel A839977 A-839977 Inhibitor inhibitor inhibit